Company profile
Iovance Biotherapeutics, Inc.
NASDAQ: IOVA · Healthcare · Biotechnology
#264 of 1,422 Healthcare companies by revenuetop-quartile growth
EA Score
59CFH 53DQ 64GM —SS 80
v0.1 · 55/100 weight · provisional
↑ market scale, workforce scale · ↓ operating margin, net margin
Methodology →Revenue TTM
$285.6M
Rev growth YoY (TTM)
+34.3%
Net income (FY)
-$391.0M
Employees
975
as of 2026-08-09
Market cap
$2.8B
as of 2026-08-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$263.5M$263.5M2025
Net income-$391.0M-$391.0M2025
Operating income-$403.4M-$403.4M2025
Total assets$913.2M$913.2M2025
Liabilities$214.6M$214.6M2025
Equity$698.6M$698.6M2025
Revenue trend
FY2017 – FY2025 · USD
FY17
FY18
FY18
FY18
FY18
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Iovance Biotherapeutics, Inc.’s revenue?
Iovance Biotherapeutics, Inc. booked $263.5M in FY2025 revenue, growing 61% year over year — faster than most Healthcare companies we track, at a -148.4% net margin.
Peers · Healthcare
Vireo Growth Inc.59CLigand Pharmaceuticals Incorporated80B+CareRx Corporation71BJushi Holdings Inc.54DArvinas, Inc.61CTerrAscend Corp.55CNeighbors
San Mateo →Key facts
CEOFrederick G. Vogt
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Carlos, CA
ExchangeNASDAQ: IOVA
Employees975
IPO date2010-10-15
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.